Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
John M. Evans Insider Profile
11 Followers
John M. Evans, CEO, Director at Beam Therapeutics, holds 1.04M shares in Beam Therapeutics (Ticker: BEAM), holds ― shares in Verve Therapeutics (Ticker: VERV).
Profitable Transactions
2 out of 2 Profitable Transactions
Average Return
+49.70%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that John M. Evans holds in companies
Most Profitable Insider Trade
The most profitable trade made by John M. Evans
John M. Evans's Trading History
Beam Therapeutics
Oct 02, 2024
CEO, Director
Uninformative Sell
1.48M
$31.61M
Verve Therapeutics
―
Director
―
―
List of latest transactions for each holding click on a transaction to see John M. Evans's performance on stock
You May Also Like
John M. Evans insider profile FAQ
What is the percentage of profitable transactions made by John M. Evans?
The percentage of profitable transactions made by John M. Evans is 100%.
What is the average return per transaction made by John M. Evans?
The average return per transaction made by John M. Evans is 49.70%.
What stocks does John M. Evans hold?
John M. Evans holds: BEAM, VERV stocks.
What was John M. Evans’s latest transaction?
John M. Evans latest transaction was an Uninformative Sell of $1.48M.
What was John M. Evans's most profitable transaction?
John M. Evans’s most profitable transaction was an Informative Sell of BEAM stock on April 4, 2022. The return on the trade was 52.50%.
What is John M. Evans's role in Beam Therapeutics?
John M. Evans's role in Beam Therapeutics is CEO, Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.